Department of Internal Medicine, University of Turin, C.so A.M. Dogliotti 14, 10126 Turin, Italy.
J Endocrinol Invest. 2013 Sep;36(8):600-5. doi: 10.3275/8883. Epub 2013 Feb 27.
Several studies investigated the possible role of adipokines during chronic viral hepatitis, not producing defined results neither clearly establishing their behavior in course of anti-viral treatment. Our study evaluated blood concentrations of adiponectin and resistin in patients with chronic hepatitis C (CHC), B (CHB), and D (CHD) receiving anti-viral treatment, at baseline and after therapy.
We examined 122 subjects, divided into two groups: 64 patients with chronic hepatitis C virus (HCV) infection (38 males and 26 females, mean age 47.25 yr) and 58 patients including 39 ones with chronic hepatitis B virus (HBV) infection (26 males and 13 females, mean age 48.46 yr) and 19 ones with chronic HBV-hepatitis D virus (HDV) infection (15 males and 4 females, mean age 45.79 yr). Serum levels of adiponectin and resistin were assayed by enzyme-linked immunosorbent assay.
In the group of CHC patients we observed a significant decrease in resistin after therapy (p=0.006), while not a significant increase in adiponectin after treatment (p=0.32). Evaluation of changes in adiponectin and resistin levels after anti-viral treatment, both in responders and non-responders, revealed no significant variations. In the group of HBV+ and HBV-HDV+ patients, we found a decrease in resistin after therapy (p=0.0016) and a not significant reduction in adiponectin after treatment (p=0.13). Furthermore, we noticed a significant reduction of resistin (p=0.006) in the sub-group of responders.
Our data suggested the possible marker role of adiponectin and resistin in the inflammatory process in course of chronic viral hepatitis.
多项研究调查了脂肪因子在慢性病毒性肝炎中的可能作用，但并未得出明确的结果，也未明确其在抗病毒治疗过程中的行为。我们的研究评估了接受抗病毒治疗的慢性丙型肝炎（CHC）、乙型肝炎（CHB）和丁型肝炎（CHD）患者的血液中脂联素和抵抗素浓度，在基线和治疗后进行了评估。
我们检查了 122 名患者，分为两组：64 名慢性丙型肝炎病毒（HCV）感染患者（38 名男性和 26 名女性，平均年龄 47.25 岁）和 58 名患者，包括 39 名慢性乙型肝炎病毒（HBV）感染患者（26 名男性和 13 名女性，平均年龄 48.46 岁）和 19 名慢性 HBV-丁型肝炎病毒（HDV）感染患者（15 名男性和 4 名女性，平均年龄 45.79 岁）。通过酶联免疫吸附试验测定脂联素和抵抗素的血清水平。
在 CHC 患者组中，我们观察到治疗后抵抗素显著下降（p=0.006），而治疗后脂联素无显著增加（p=0.32）。对抗病毒治疗后脂联素和抵抗素水平变化的评估，无论是在应答者还是非应答者中，均未发现显著变化。在 HBV+和 HBV-HDV+患者组中，我们发现治疗后抵抗素降低（p=0.0016），治疗后脂联素降低不显著（p=0.13）。此外，我们注意到应答者亚组中抵抗素显著降低（p=0.006）。
我们的数据表明，脂联素和抵抗素可能在慢性病毒性肝炎炎症过程中具有标记物作用。
